You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

39 Results
Guidelines and Advice
Status: Current
ID: 8-1
Version: 6
Mar 2024
Guidelines and Advice
Status: Current
ID: GL 2-21
Version: 2
Mar 2024
Drug
Other Name(s): Suprefact® , Suprefact Depot® , Suprefact Nasal Spray®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Nov 2024
Drug
Other Name(s): Casodex® (multiple brands available)
Quick Link(s):
Drug Monograph, Patient Info Sheet
Apr 2024
Drug
Quick Link(s):
Drug Monograph, Patient Info Sheet
Nov 2024
Drug
Other Name(s): Treanda®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Nov 2024
Drug
Other Name(s): Bosulif®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Nov 2024
Drug
Other Name(s): Blincyto®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Nov 2024
Regimen
Cancer Type:
Central Nervous System
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
bevacizumab (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jul 2024
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - Relapsed or Refractory Multiple Myeloma
ODB - General Benefit
    dexamethasone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
bortezomib,
dexamethasone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2024
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
bortezomib (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2024
Regimen
Cancer Type:
Gastrointestinal, 
Neuroendocrine (GI)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    SUNItinib - For patients who have progressive, unresectable, well or moderately differentiated, locally advanced or metastatic pancreatic neuroendocrine tumours (pNET), according to specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
SUNItinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2024

Pages